ethyl 9-(N-methylaminocarbonylmethyl)-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylate | 183735-83-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并[1，2-a]吡嗪-8-酮
• 英文名称: ethyl 9-(N-methylaminocarbonylmethyl)-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylate
• 英文别名: ethyl 14-[2-(methylamino)-2-oxoethyl]-7-oxo-2,5,8-triazatetracyclo[7.7.0.02,6.010,15]hexadeca-1(9),3,5,10,12,14-hexaene-4-carboxylate
• CAS: 183735-83-3
• 化学式: C₁₉H₁₈N₄O₄
• 分子量: 366.376
• InChiKey: DMKGTPVAYZSLEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 9-(N-methylaminocarbonylmethyl)-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylate 在 氢溴酸 作用下， 生成 9-N-methylaminocarbonylmethyl-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid
  参考文献：
  名称：

  Bioisosteres of 9-Carboxymethyl-4-oxo-imidazo[1,2- a ]indeno[1,2- e ]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent In Vivo AMPA antagonists with longer durations of action

  摘要：

  A novel series of 2- and 9-disubstituted heterocyclic-fused 4-oxo-indeno[1,2-e]pyrazin derivatives was synthesized. One of them, the 9-(1 H-tetrazol-5-ylmethyl)-4-oxo-5,10-dihydroimidazo[1,2-a]indeno[1,2-e]pyrazin-2-yl phosphonic acid 4i exhibited a strong and a selective binding affinity for the AMPA receptor (IC50 = 13 nM) and demonstrated potent antagonist activity (IC50 = 6 nM) at the ionotropic AMPA receptor. This compound also displayed good anticonvulsant properties against electrically-induced convulsions after ip and iv administration with ED50 values between 0.8 and 1 mg/kg. Furthermore, a strong increase in potency was observed when given iv 3 h before test (ED50 = 3.5 instead of 25.6 mg/kg for the corresponding 9-carboxymethyl-2-carboxylic acid analogue). These data confirmed that there is an advantage in replacing the classical carboxy substituents by their bioisosteres such as tetrazole or phosphonic acid groups. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00592-8
• 作为产物：
  描述：

  3-[2-(羧甲基)苯基]丙酸 在 18-冠醚-6 、 硫酸 、 ammonium acetate 、 溴 、 potassium carbonate 、 溶剂黄146 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 为溶剂， 反应 2.0h， 生成 ethyl 9-(N-methylaminocarbonylmethyl)-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylate
  参考文献：
  名称：

  Bioisosteres of 9-Carboxymethyl-4-oxo-imidazo[1,2- a ]indeno[1,2- e ]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent In Vivo AMPA antagonists with longer durations of action

  摘要：

  A novel series of 2- and 9-disubstituted heterocyclic-fused 4-oxo-indeno[1,2-e]pyrazin derivatives was synthesized. One of them, the 9-(1 H-tetrazol-5-ylmethyl)-4-oxo-5,10-dihydroimidazo[1,2-a]indeno[1,2-e]pyrazin-2-yl phosphonic acid 4i exhibited a strong and a selective binding affinity for the AMPA receptor (IC50 = 13 nM) and demonstrated potent antagonist activity (IC50 = 6 nM) at the ionotropic AMPA receptor. This compound also displayed good anticonvulsant properties against electrically-induced convulsions after ip and iv administration with ED50 values between 0.8 and 1 mg/kg. Furthermore, a strong increase in potency was observed when given iv 3 h before test (ED50 = 3.5 instead of 25.6 mg/kg for the corresponding 9-carboxymethyl-2-carboxylic acid analogue). These data confirmed that there is an advantage in replacing the classical carboxy substituents by their bioisosteres such as tetrazole or phosphonic acid groups. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00592-8

文献信息

• 5H,10H-imidazo\x9b1,2-a!indeno\x9b1,2-e!pyrazin-4-one derivatives, preparation
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05902803A1

  公开（公告）日：1999-05-11

  Compounds of formula (I), wherein R is a hydrogen atom or a carboxy, alkoxycarbonyl, --CO--NR.sub.4 R.sub.5, --PO.sub.3 H.sub.2 or --CH.sub.2 OH radical, and R.sub.1 is an -alk-NH.sub.2, -alk-NH--CO--R.sub.3, -alk-COOR.sub.4, -alk-CO--NR.sub.5 R.sub.6 or --CO--NH--R.sub.7 radical. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartame (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.

  式(I)化合物，其中R为氢原子或羧基、烷氧羰基、--CO--NR₄R₅、--PO₃H₂或--CH₂OH基团，R₁为-烷基-NH₂、-烷基-NH--CO--R₃、-烷基-COOR₄、-烷基-CO--NR₅R₆或--CO--NH--R₇基团。式(I)化合物具有宝贵的药理特性，是α-氨基-3-羟基-5-甲基-4-异噁唑丙酸(AMPA)受体即quisqualate受体的拮抗剂。此外，式(I)化合物是非竞争性N-甲基-D-天冬氨酸(NMDA)受体的拮抗剂，更具体地说是NMDA受体甘氨酸调节位点的配体。
• 1-oxo-1H-inden-2-yl-1H-imidazole-2-carboxylic acid intermediates
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US06057454A1

  公开（公告）日：2000-05-02

  A compound of formula (II): ##STR1## in which R is a hydrogen atom or a carboxy, alkoxycarbonyl, --CO--NR.sub.4 R.sub.5, --PO.sub.3 H.sub.2 or --CH.sub.2 OH radical, and R.sub.1 is an -alk-NH.sub.2, -alk-NH--CO--R.sub.3, -alk-COOR.sub.4, -alk-CO--NR.sub.5 R.sub.6 or --CO--NH--R.sub.7 radical. The compounds of formula (II) can be used to prepare compounds of formula (I): ##STR2## in which R and R.sub.1 have the same meanings as above. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, also known as the quisqualate receptor. The compounds of formula (I) are also non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.

  式（II）的化合物：##STR1## 其中R是氢原子或羧基，烷氧羰基，--CO--NR.sub.4 R.sub.5，--PO.sub.3 H.sub.2或--CH.sub.2 OH基团，而R.sub.1是-烷基-NH.sub.2，-烷基-NH--CO--R.sub.3，-烷基-COOR.sub.4，-烷基-CO--NR.sub.5 R.sub.6或--CO--NH--R.sub.7基团。式（II）的化合物可用于制备式（I）的化合物：##STR2## 其中R和R.sub.1与上述含义相同。式（I）的化合物具有有价值的药理学特性，并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA）受体的拮抗剂，也称为石菜酸受体。式（I）的化合物也是N-甲基-D-天门冬氨酸（NMDA）受体的非竞争性拮抗剂，更具体地说是NMDA受体甘氨酸调节剂位点的配体。
• US6057454A
  申请人：——

  公开号：US6057454A

  公开（公告）日：2000-05-02